Infections/Febrile Episodes During Remission of CLL Patients Receiving Fludarabine Regimens as Initial Therapy
| Characteristic . | Value . | No. of Patients . | No. of Episodes . | Years at Risk . | Incidence . |
|---|---|---|---|---|---|
| Regimen | No Pred | 57 | 28 | 142.98 | 1/5.11 |
| Pred | 80 | 66 | 170.34 | 1/2.58 | |
| CD4 count at end of Rx | <100/μL | 31 | 27 | 82.05 | 1/3.03 |
| 100-200/μL | 31 | 21 | 68.06 | 1/3.24 | |
| >200/μL | 30 | 21 | 61.39 | 1/2.92 | |
| Total | — | 137 | 94 | 313.32 | 1/3.33 |
| Characteristic . | Value . | No. of Patients . | No. of Episodes . | Years at Risk . | Incidence . |
|---|---|---|---|---|---|
| Regimen | No Pred | 57 | 28 | 142.98 | 1/5.11 |
| Pred | 80 | 66 | 170.34 | 1/2.58 | |
| CD4 count at end of Rx | <100/μL | 31 | 27 | 82.05 | 1/3.03 |
| 100-200/μL | 31 | 21 | 68.06 | 1/3.24 | |
| >200/μL | 30 | 21 | 61.39 | 1/2.92 | |
| Total | — | 137 | 94 | 313.32 | 1/3.33 |